We Doctor Holdings Limited Files for IPO on Hong Kong Stock Exchange
China-based We Doctor Holdings Limited, a subsidiary of Chinese internet giant Tencent Corporate Venture Capital...
IPO
GenFleet Therapeutics Submits IPO Application to HKEX, Backed by CITIC Securities
On December 27, 2024, GenFleet Therapeutics, a biopharmaceutical company based in Shanghai, submitted its application...
Dynamiker Biotechnology Receives Approval for IPO on Beijing Stock Exchange
On December 27, 2024, the official website of the Beijing Stock Exchange announced that Dynamiker...
Ascentage Pharma Announces Secondary Offering on Nasdaq, Expanding Global Reach
China-based Ascentage Pharma (HKG: 6855) has unveiled plans for a secondary offering of up to...
Biopharma Company TransThera Sciences (Nanjing) Gets Green Light for HK IPO
On December 20, 2024, the China Securities Regulatory Commission confirmed the listing filing for TransThera...
iFlytek’s Subsidiary Xunfei Healthcare Technologies Lists on HKEX, Raises Over HKD 580 Million
Xunfei Healthcare Technology Co., Ltd, a subsidiary of China-based information technology company iFlytek Co., Ltd...
HealthyWay Inc. Completes HKD 220 Million IPO on the Hong Kong Stock Exchange
China-based HealthyWay Inc. (HKG: 2587) has made a significant debut on the Hong Kong Stock...
iFlytek’s Xunfei Healthcare Passes HKEX Hearing for AI-Powered Medical IPO
Xunfei Healthcare Technology Co., Ltd., a subsidiary of China’s leading information technology company iFlytek Co.,...
Mabwell Bioscience Plans Secondary Listing in Hong Kong, Secures Funding for Bone Health Project
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) is set to make a secondary listing on...
Sunshine Lake Pharma Files for HKEX IPO, Expanding Global Pharmaceutical Reach
China-based Sunshine Lake Pharma Co., Ltd has submitted an initial public offering (IPO) filing to...
Jiangsu Hengrui Pharmaceuticals Plans Secondary Listing on Hong Kong Stock Exchange
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has confirmed reports regarding its intention to make...
Medtide Inc. Submits Second IPO Application to Hong Kong Stock Exchange
Medtide Inc., a Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in polypeptides and based...
Guangzhou Innogen Pharmaceutical Files for IPO on Hong Kong Stock Exchange
Guangzhou Innogen Pharmaceutical Group Co., Ltd., a China-based pharmaceutical company, has made an initial public...
Ophthalmology Biotech Cloudbreak Pharma Inc. Pursues Hong Kong IPO
Cloudbreak Pharma Inc., a Cayman Island-registered ophthalmology biotech company, has filed for an initial public...
Shanghai Cell Therapy Group’s Second Attempt at HK IPO Receives Green Light from CICC and CCB International
Shanghai Cell Therapy Group Co., Ltd., a leading player in China’s cellular medical health sector,...
Nanjing Leads Biolabs Commences IPO Process with Focus on Innovative Therapies
Nanjing Leads Biolabs Co., Ltd., a clinical-stage biopharmaceutical company focused on developing innovative therapies for...
Hanx Biopharmaceuticals Files for IPO on Hong Kong Stock Exchange
China-based Hanx Biopharmaceuticals (Wuhan) Co., Ltd. has made an initial public offering (IPO) filing to...
Chinese Biopharma Bio-Bank Corp. Aims for HKEX IPO, Focused on PDGF Therapies
On November 22, 2024, B&K Corporation Limited (Bio-Bank Corp.), a biopharmaceutical company headquartered in China,...
Hangzhou Jiuyuan Gene Engineering Plans HKEX IPO to Raise Up to USD 73.2 Million
Hangzhou Jiuyuan Gene Engineering Co., Ltd. is poised to conduct an initial public offering (IPO)...
Hangzhou Jiuyuan Gene Engineering Passes HKEX IPO Hearing for Orthopedic Treatments
Hangzhou Jiuyuan Gene Engineering Co., Ltd. has announced that it has successfully passed the listing...